Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
J Wenzel - Nature Reviews Rheumatology, 2019 - nature.com
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can present as an
isolated skin disease or as a manifestation within the spectrum of systemic lupus …
isolated skin disease or as a manifestation within the spectrum of systemic lupus …
Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus
Despite the success of targeted therapies in managing immune-mediated inflammatory
diseases (IMIDs) such as RA, IBDs, MS and psoriasis, unmet needs for such approach in …
diseases (IMIDs) such as RA, IBDs, MS and psoriasis, unmet needs for such approach in …
S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of …
A Kuhn, E Aberer, Z Bata‐Csörgő… - Journal of the …, 2017 - Wiley Online Library
Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with
heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed …
heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed …
IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment
A Zickert, P Amoudruz, Y Sundström, J Rönnelid… - BMC immunology, 2015 - Springer
Background Recent studies indicate a central role for the IL-23/IL-17 axis in the
pathogenesis of lupus nephritis (LN) but the importance in the context of treatment outcome …
pathogenesis of lupus nephritis (LN) but the importance in the context of treatment outcome …
T cells and IL-17 in lupus nephritis
T Koga, K Ichinose, GC Tsokos - Clinical immunology, 2017 - Elsevier
Systemic lupus erythematosus (SLE) is a complicated autoimmune disorder characterized
by autoantibodies production, immune complex formation, and immune dysregulation …
by autoantibodies production, immune complex formation, and immune dysregulation …
Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus
T Koga, K Ichinose, A Kawakami… - Frontiers in …, 2021 - frontiersin.org
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune
cell abnormalities which lead to the production of autoantibodies and the deposition of …
cell abnormalities which lead to the production of autoantibodies and the deposition of …
The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
T Koga, K Ichinose, A Kawakami… - Expert review of clinical …, 2019 - Taylor & Francis
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized
by autoantibodies production and immune complex deposition with systemic clinical …
by autoantibodies production and immune complex deposition with systemic clinical …
Beyond pan-B-cell-directed therapy—new avenues and insights into the pathogenesis of SLE
New insights into the mechanisms of autoimmune diseases have been obtained not only
from preclinical studies, but also from clinical trials of pan-B-cell-directed therapy. Overall …
from preclinical studies, but also from clinical trials of pan-B-cell-directed therapy. Overall …
Current insights in cutaneous lupus erythematosus immunopathogenesis
CJ Garelli, MA Refat, PP Nanaware… - Frontiers in …, 2020 - frontiersin.org
Cutaneous Lupus Erythematosus (CLE) is a clinically diverse group of autoimmune skin
diseases with shared histological features of interface dermatitis and autoantibodies …
diseases with shared histological features of interface dermatitis and autoantibodies …
The star target in SLE: IL-17
Y Yang, C Yan, L Yu, X Zhang, J Shang, J Fan… - Inflammation …, 2023 - Springer
Purpose The purpose of this review is to discuss the significance of IL-17 in SLE and the
potential of IL-17-targeted therapy. Background Systemic lupus erythematosus (SLE) is an …
potential of IL-17-targeted therapy. Background Systemic lupus erythematosus (SLE) is an …